vs
CARLISLE COMPANIES INC（CSL）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
CARLISLE COMPANIES INC的季度营收约是ICU MEDICAL INC的1.9倍（$1.1B vs $540.7M），CARLISLE COMPANIES INC净利率更高（12.1% vs -2.9%，领先15.0%），CARLISLE COMPANIES INC同比增速更快（-4.0% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-73.0M），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -14.8%）
卡莱尔公司是专业建筑产品供应商，聚焦于提升建筑能效与稳固性，面向商业建筑领域生产销售单层屋面产品、质保系统及配套配件，旗下设有卡莱尔建筑材料、卡莱尔防水技术两大业务板块，产品涵盖防潮材料、屋面防护层等多个品类。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
CSL vs ICUI — 直观对比
营收规模更大
CSL
是对方的1.9倍
$540.7M
营收增速更快
CSL
高出10.2%
-14.1%
净利率更高
CSL
高出15.0%
-2.9%
自由现金流更多
ICUI
多$109.0M
$-73.0M
两年增速更快
ICUI
近两年复合增速
-14.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $540.7M |
| 净利润 | $127.7M | $-15.7M |
| 毛利率 | 34.5% | 37.5% |
| 营业利润率 | 17.1% | 1.0% |
| 净利率 | 12.1% | -2.9% |
| 营收同比 | -4.0% | -14.1% |
| 净利润同比 | -10.9% | 34.0% |
| 每股收益（稀释后） | $3.10 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSLICUI
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $540.7M | ||
| Q3 25 | $1.3B | $537.0M | ||
| Q2 25 | $1.4B | $548.9M | ||
| Q1 25 | $1.1B | $604.7M | ||
| Q4 24 | $1.1B | $629.8M | ||
| Q3 24 | $1.3B | $589.1M | ||
| Q2 24 | $1.5B | $596.5M |
净利润CSLICUI
| Q1 26 | $127.7M | — | ||
| Q4 25 | $127.4M | $-15.7M | ||
| Q3 25 | $214.2M | $-3.4M | ||
| Q2 25 | $255.8M | $35.3M | ||
| Q1 25 | $143.3M | $-15.5M | ||
| Q4 24 | $162.8M | $-23.8M | ||
| Q3 24 | $244.3M | $-33.0M | ||
| Q2 24 | $712.4M | $-21.4M |
毛利率CSLICUI
| Q1 26 | 34.5% | — | ||
| Q4 25 | 33.8% | 37.5% | ||
| Q3 25 | 36.0% | 37.4% | ||
| Q2 25 | 37.3% | 37.9% | ||
| Q1 25 | 35.2% | 34.7% | ||
| Q4 24 | 36.1% | 36.1% | ||
| Q3 24 | 38.6% | 34.8% | ||
| Q2 24 | 39.2% | 34.8% |
营业利润率CSLICUI
| Q1 26 | 17.1% | — | ||
| Q4 25 | 16.8% | 1.0% | ||
| Q3 25 | 21.8% | 2.6% | ||
| Q2 25 | 23.1% | 1.9% | ||
| Q1 25 | 16.8% | 2.1% | ||
| Q4 24 | 19.9% | 6.0% | ||
| Q3 24 | 23.7% | 1.4% | ||
| Q2 24 | 26.0% | 1.3% |
净利率CSLICUI
| Q1 26 | 12.1% | — | ||
| Q4 25 | 11.3% | -2.9% | ||
| Q3 25 | 15.9% | -0.6% | ||
| Q2 25 | 17.6% | 6.4% | ||
| Q1 25 | 13.1% | -2.6% | ||
| Q4 24 | 14.5% | -3.8% | ||
| Q3 24 | 18.3% | -5.6% | ||
| Q2 24 | 49.1% | -3.6% |
每股收益（稀释后）CSLICUI
| Q1 26 | $3.10 | — | ||
| Q4 25 | $3.06 | $-0.63 | ||
| Q3 25 | $4.98 | $-0.14 | ||
| Q2 25 | $5.88 | $1.43 | ||
| Q1 25 | $3.20 | $-0.63 | ||
| Q4 24 | $3.76 | $-0.97 | ||
| Q3 24 | $5.25 | $-1.35 | ||
| Q2 24 | $14.84 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $771.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.7B | $2.1B |
| 总资产 | — | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSLICUI
| Q1 26 | $771.3M | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $68.4M | — | ||
| Q1 25 | $220.2M | — | ||
| Q4 24 | $753.5M | $308.6M | ||
| Q3 24 | $1.5B | $312.5M | ||
| Q2 24 | $1.7B | $302.6M |
总债务CSLICUI
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
股东权益CSLICUI
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.8B | $2.1B | ||
| Q3 25 | $2.0B | $2.1B | ||
| Q2 25 | $2.1B | $2.1B | ||
| Q1 25 | $2.2B | $2.0B | ||
| Q4 24 | $2.5B | $2.0B | ||
| Q3 24 | $2.8B | $2.0B | ||
| Q2 24 | $3.0B | $2.0B |
总资产CSLICUI
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | $4.1B | ||
| Q3 25 | $6.5B | $4.1B | ||
| Q2 25 | $5.5B | $4.1B | ||
| Q1 25 | $5.5B | $4.2B | ||
| Q4 24 | $5.8B | $4.2B | ||
| Q3 24 | $6.5B | $4.3B | ||
| Q2 24 | $6.7B | $4.3B |
负债/权益比CSLICUI
| Q1 26 | — | — | ||
| Q4 25 | 1.61× | — | ||
| Q3 25 | 1.45× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 0.77× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.76× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | $36.0M |
| 自由现金流率自由现金流/营收 | -6.9% | 6.6% |
| 资本支出强度资本支出/营收 | 2.7% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $924.8M | $91.8M |
8季度趋势，按日历期对齐
经营现金流CSLICUI
| Q1 26 | — | — | ||
| Q4 25 | $386.0M | $60.6M | ||
| Q3 25 | $426.9M | $56.7M | ||
| Q2 25 | $287.1M | $11.2M | ||
| Q1 25 | $1.8M | $51.3M | ||
| Q4 24 | $370.6M | $40.2M | ||
| Q3 24 | $312.8M | $36.1M | ||
| Q2 24 | $183.4M | $82.0M |
自由现金流CSLICUI
| Q1 26 | $-73.0M | — | ||
| Q4 25 | $346.1M | $36.0M | ||
| Q3 25 | $393.4M | $27.6M | ||
| Q2 25 | $258.3M | $-8.5M | ||
| Q1 25 | $-27.2M | $36.7M | ||
| Q4 24 | $334.0M | $16.1M | ||
| Q3 24 | $293.5M | $16.2M | ||
| Q2 24 | $158.5M | $62.5M |
自由现金流率CSLICUI
| Q1 26 | -6.9% | — | ||
| Q4 25 | 30.7% | 6.6% | ||
| Q3 25 | 29.2% | 5.1% | ||
| Q2 25 | 17.8% | -1.5% | ||
| Q1 25 | -2.5% | 6.1% | ||
| Q4 24 | 29.7% | 2.6% | ||
| Q3 24 | 22.0% | 2.7% | ||
| Q2 24 | 10.9% | 10.5% |
资本支出强度CSLICUI
| Q1 26 | 2.7% | — | ||
| Q4 25 | 3.5% | 4.6% | ||
| Q3 25 | 2.5% | 5.4% | ||
| Q2 25 | 2.0% | 3.6% | ||
| Q1 25 | 2.6% | 2.4% | ||
| Q4 24 | 3.3% | 3.8% | ||
| Q3 24 | 1.4% | 3.4% | ||
| Q2 24 | 1.7% | 3.3% |
现金转化率CSLICUI
| Q1 26 | — | — | ||
| Q4 25 | 3.03× | — | ||
| Q3 25 | 1.99× | — | ||
| Q2 25 | 1.12× | 0.32× | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 2.28× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 0.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSL
| CCM | $758.0M | 72% |
| CWT | $294.0M | 28% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
